"VitaMed" LLC
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Poddubskaya, Elena V
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Recruiting
3
410
RoW
BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy
Biocad
Melanoma Stage III, Melanoma (Skin)
01/27
06/27
Yakovleva, Natalia
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Poddubskaya, Elena V
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Recruiting
3
410
RoW
BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy
Biocad
Melanoma Stage III, Melanoma (Skin)
01/27
06/27
Yakovleva, Natalia
No trials found

Download Options